The study appeared online Monday and in an upcoming print issue of The Lancet.
"Although we recognize the slightly increased risk of lymphoma, these agents will probably remain one of the cornerstones of treatment. Nonetheless, physicians should be cautious when prolonged combined and deep immunosuppression is needed to achieve disease control," Dr. Geert D'Haens, of the Imelda GI Clinical Research Centre and University Hospital Gasthuisberg in Belgium, and Dr. Paul Rutgeerts, University Hospital Gasthuisberg, wrote in an accompanying editorial.
More information
The Crohn's and Colitis Foundation of America has more about IBD.
-- Robert Preidt
SOURCE: The Lancet, news release, Oct. 18, 2009
| Copyright©2009 ScoutNews,LLC. All rights reserved |